Internal Medicine, Infectious Disease · Orlando, FL
NPI
1427215557
Since 2008
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1707 N Mills Ave
Orlando, FL, 32803
Phone (407) 647-3960
Groups this clinician bills Medicare through
Medicare paid, 2024
$73K
914 services
Medicare patients, 2024
294
Average age 66
Drug cost, 2024
$12.5M
6,122 prescriptions
Company payments, 2025
$52K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Federico Hinestrosa was code 99214 (office e&m - established), 392 times for 232 patients. In total Federico Hinestrosa billed 914 services in 34 codes, and Medicare paid $73K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-05-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 392 | 232 | $87.48 | $34K |
| 99213 Office E&M - Established | Office | 200 | 135 | $64.87 | $13K |
| 90661 Vaccine Product | Office | 38 | 38 | $35.06 | $1,332 |
| G0008 Administration of influenza virus vaccine | Office | 35 | 35 | $31.66 | $1,108 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 28 | 28 | $135.81 | $3,803 |
| 96372 Injection Administration | Office | 26 | 14 | $10.03 | $261 |
| 91320 Vaccine Product | Office | 23 | 22 | $146.39 | $3,367 |
| 90480 Vaccine Administration | Office | 23 | 22 | $42.22 | $971 |
| 46606 Digestive/Gastrointestinal | Office | 16 | 16 | $221.54 | $3,545 |
| 99215 Office E&M - Established | Office | 13 | 13 | $132.55 | $1,723 |
By year: 2022 $68K for 1,089 services; 2023 $67K for 998 services; 2024 $73K for 914 services.
Medicare prescription drug claims, 2024
In 2024, the drug Federico Hinestrosa prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 1,431 prescriptions and refills. In total Federico Hinestrosa wrote 6,122 Medicare prescriptions that cost $12.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 1,431 | 1,445 | 155 | $5.8M |
| Dovato Dolutegravir Sodium/Lamivudine | 503 | 523 | 54 | $1.6M |
| Tivicay Dolutegravir Sodium | 274 | 284 | 32 | $708K |
| Prezcobix Darunavir/Cobicistat | 191 | 191 | 22 | $466K |
| Rosuvastatin Calcium Generic | 161 | 389 | 43 | $2,125 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 142 | 142 | 16 | $596K |
| Descovy Emtricitabine/Tenofov Alafenam | 140 | 158 | 18 | $360K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 131 | 137 | 14 | $499K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 124 | 124 | 14 | $608K |
| Pifeltro Doravirine | 118 | 124 | 15 | $212K |
| Valacyclovir Valacyclovir Hcl | 118 | 190 | 25 | $4,831 |
| Juluca Dolutegravir/Rilpivirine | 96 | 98 | 13 | $368K |
| Atorvastatin Calcium Generic | 88 | 207 | 23 | $613 |
| Alprazolam Generic | 88 | 98 | 14 | $702 |
| Gabapentin Generic | 81 | 109 | 11 | $1,155 |
Brand drugs: 3,725 claims; generic drugs: - claims; opioid claims: 48.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Federico Hinestrosa $52K ($50K in general payments such as food, travel and fees and $1,514 for research) from 10 companies. The largest payer was Gilead Sciences, Inc. with $41K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 76 | $41K |
| Merck Sharp & Dohme LLC MRK | 31 | $5,611 |
| ViiV Healthcare Company GSK | 73 | $3,937 |
| Theratechnologies Inc. THTX | 9 | $1,072 |
| Abbvie Inc. ABBV | 1 | $23.46 |
| Tolmar, Inc. | 1 | $23.06 |
| Napo Pharmaceuticals Inc | 1 | $20.34 |
| Lilly USA, LLC LLY | 1 | $17.26 |
| GlaxoSmithKline, LLC. GSK | 1 | $15.66 |
| Pfizer Inc. PFE | 1 | $14.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.